Credit Suisse Ag Vertex Pharmaceuticals Inc Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Credit Suisse Ag holds 349,294 shares of VRTX stock, worth $165 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares

349,294

Previous 392,325 10.97%

Holding current value

$165 Million

Previous $160 Million 8.54%

% of portfolio

0.14%

Previous 0.16%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$407.69 - $446.08 $17.5 Million - $19.2 Million	-43,031 Reduced 10.97%	349,294 $146 Million
Q4 2023 Feb 08, 2024	SELL	$343.0 - $410.68 $35.5 Million - $42.6 Million	-103,643 Reduced 20.9%	392,325 $160 Million
Q3 2023 Nov 13, 2023	BUY	$338.18 - $362.46 $31.9 Million - $34.2 Million	94,244 Added 23.46%	495,968 $172 Million
Q2 2023 Aug 11, 2023	SELL	$314.42 - $351.91 $51.1 Million - $57.1 Million	-162,366 Reduced 28.78%	401,724 $141 Million
Q1 2023 May 10, 2023	BUY	$283.23 - $323.1 $3.26 Million - $3.71 Million	11,494 Added 2.08%	564,090 $178 Million

Q4 2022 Feb 13, 2023	SELL	$285.76 - $321.48 $6.56 Million - $7.38 Million	-22,963 Reduced 3.99%	552,596 $160 Million
Q3 2022 Nov 10, 2022	SELL	$273.83 - $305.53 $41.3 Million - $46.1 Million	-150,896 Reduced 20.77%	575,559 $167 Million
Q2 2022 Aug 12, 2022	BUY	$234.96 - $292.55 $15.3 Million - $19 Million	64,980 Added 9.82%	726,455 $205 Million
Q1 2022 May 16, 2022	BUY	$221.42 - $260.97 $7.08 Million - $8.35 Million	31,980 Added 5.08%	661,475 $173 Million
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $3.96 Million - $5 Million	22,364 Added 3.68%	629,495 $138 Million
Q3 2021 Nov 12, 2021	SELL	$181.39 - $202.99 $13.1 Million - $14.6 Million	-72,085 Reduced 10.61%	607,131 $110 Million
Q2 2021 Aug 16, 2021	SELL	$187.49 - $221.1 $103 Million - $122 Million	-551,132 Reduced 44.79%	679,216 $137 Million
Q1 2021 May 14, 2021	BUY	$207.02 - $241.31 $105 Million - $123 Million	508,592 Added 70.47%	1,230,348 $264 Million
Q4 2020 Feb 12, 2021	BUY	$207.01 - $276.09 $1.68 Million - $2.24 Million	8,107 Added 1.14%	721,756 $171 Million
Q3 2020 Nov 13, 2020	SELL	$255.65 - $303.1 $20.7 Million - $24.5 Million	-80,795 Reduced 10.17%	713,649 $194 Million
Q2 2020 Aug 12, 2020	BUY	$225.48 - $295.8 $60.5 Million - $79.4 Million	268,279 Added 50.99%	794,444 $231 Million
Q1 2020 May 13, 2020	BUY	$199.77 - $247.81 $9.17 Million - $11.4 Million	45,902 Added 9.56%	526,165 $125 Million
Q4 2019 Feb 12, 2020	BUY	$166.71 - $223.91 $31 Million - $41.6 Million	185,660 Added 63.02%	480,263 $105 Million
Q3 2019 Nov 12, 2019	SELL	$166.23 - $187.09 $19.6 Million - $22.1 Million	-118,171 Reduced 28.63%	294,603 $49.9 Million
Q2 2019 Aug 14, 2019	BUY	$164.61 - $190.37 $5.22 Million - $6.04 Million	31,706 Added 8.32%	412,774 $75.7 Million
Q1 2019 May 14, 2019	BUY	$163.73 - $194.7 $5.58 Million - $6.64 Million	34,092 Added 9.83%	381,068 $70.1 Million
Q4 2018 Feb 13, 2019	SELL	$151.91 - $192.21 $979,971 - $1.24 Million	-6,451 Reduced 1.83%	346,976 $57.5 Million
Q3 2018 Nov 13, 2018	BUY	$167.73 - $192.74 $7.59 Million - $8.72 Million	45,223 Added 14.67%	353,427 $68.1 Million
Q2 2018 Aug 14, 2018	SELL	$145.72 - $169.96 $32.4 Million - $37.7 Million	-222,026 Reduced 41.87%	308,204 $52.4 Million
Q1 2018 May 15, 2018	BUY	$151.6 - $177.13 $5.49 Million - $6.41 Million	36,192 Added 7.33%	530,230 $86.4 Million
Q4 2017 Feb 14, 2018	BUY	$137.28 - $155.55 $5.61 Million - $6.36 Million	40,887 Added 9.02%	494,038 $74 Million
Q3 2017 Nov 14, 2017	SELL	$148.13 - $162.24 $15.1 Million - $16.5 Million	-101,761 Reduced 18.34%	453,151 $68.9 Million
Q2 2017 Aug 14, 2017	BUY	N/A	554,912	554,912 $71.5 Million

Others Institutions Holding VRTX

# of Institutions

1,624

Shares Held

222M

Call Options Held

1.35M

Put Options Held

1.49M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $122B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account